Related Experiment Video

Updated: Jun 1, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Histone deacetylase inhibition as an anticancer telomerase-targeting strategy

Ruman Rahman1, Richard Grundy

  • 1Children's Brain Tumor Research Centre, University of Nottingham, UK. ruman.rahman@nottingham.ac.uk

International Journal of Cancer
|June 15, 2011
PubMed

Insights

Histone deacetylase inhibitors (HDACi) show promise in cancer treatment by correcting epigenetic errors. This study highlights how HDACi may work by restoring proper acetylation balance at the hTERT promoter, impacting cancer growth.

Area of Science:

  • Epigenetics and Cancer Biology
  • Pharmacology of Anticancer Agents

Background:

  • Aberrant epigenetic regulation is a key driver of tumor initiation and progression.
  • Histone deacetylase inhibitors (HDACi) are recognized for their potent anticancer effects across various tumor types.
  • The precise mechanisms underlying HDACi's efficacy in inhibiting cancer growth and inducing cell death require further elucidation.

Purpose of the Study:

  • To explore the role of epigenetic dysregulation of human telomerase reverse transcriptase (hTERT) transcription in cancer.
  • To propose that HDACi exert anticancer effects by correcting the acetylation-deacetylation balance at the hTERT promoter.
  • To discuss future perspectives in HDACi research, including cancer stem cells and therapeutic resistance.

Main Methods:

  • Review and discussion of existing preclinical and early clinical studies on HDACi.
  • Focus on epigenetic mechanisms, specifically concerning hTERT gene regulation.
  • Analysis of the acetylation-deacetylation balance at the hTERT promoter.

Main Results:

  • Aberrant epigenetic regulation of hTERT transcription is implicated in cancer cells.
  • HDACi may induce anticancer effects by restoring a proper acetylation-deacetylation balance at the hTERT promoter.
  • The therapeutic paradigm of cancer stem cells is relevant to tumor resistance against HDACi.

Conclusions:

  • Alleviating improper acetylation-deacetylation balance at the hTERT promoter is a proposed mechanism for HDACi's anticancer activity.
  • Further research into HDACi, particularly concerning cancer stem cells and resistance, is warranted.
  • HDACi represent a promising therapeutic strategy with complex mechanisms of action.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.